O
VTRS icon

OrbiMed’s Viatris VTRS Stock Holding History

OrbiMed’s Portfolio VTRS Stock Details VTRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-535,149
Closed -$10M – 180
2020
Q4 		$10M Buy
+535,149
New +$8.73M 0.09% 122
2019
Q3 		– Sell
-1,373,305
Closed -$26.1M – 139
2019
Q2 		$26.1M Sell
1,373,305
-3,488,495
-72% -$77.1M 0.41% 58
2019
Q1 		$138M Buy
4,861,800
+875,600
+22% +$25.5M 2.13% 10
2018
Q4 		$109M Sell
3,986,200
-793,400
-17% -$25.7M 2.02% 12
2018
Q3 		$175M Buy
4,779,600
+1,076,800
+29% +$40.4M 2.11% 11
2018
Q2 		$134M Buy
3,702,800
+1,868,500
+102% +$73.3M 1.6% 14
2018
Q1 		$75.5M Hold
1,834,300
– – 0.94% 36
2017
Q4 		$77.6M Sell
1,834,300
-1,766,800
-49% -$67.5M 0.98% 35
2017
Q3 		$113M Buy
3,601,100
+621,900
+21% +$21.1M 1.08% 30
2017
Q2 		$116M Buy
2,979,200
+1,679,200
+129% +$64.4M 1.21% 25
2017
Q1 		$50.7M Buy
+1,300,000
New +$52.4M 0.57% 52
2016
Q2 		– Sell
-69,800
Closed -$3.23M – 144
2016
Q1 		$3.23M Sell
69,800
-3,087,200
-98% -$149M 0.03% 124
2015
Q4 		$171M Buy
+3,157,000
New +$152M 1.55% 20
2014
Q4 		– Sell
-169,100
Closed -$7.69M – 137
2014
Q3 		$7.69M Sell
169,100
-3,783,600
-96% -$184M 0.08% 103
2014
Q2 		$204M Buy
3,952,700
+47,200
+1% +$2.32M 2.39% 14
2014
Q1 		$191M Sell
3,905,500
-309,000
-7% -$15M 2.35% 13
2013
Q4 		$183M Sell
4,214,500
-834,500
-17% -$34.3M 2.69% 11
2013
Q3 		$193M Buy
5,049,000
+62,000
+1% +$2.18M 3.44% 7
2013
Q2 		$155M Buy
+4,987,000
New +$149M 3.28% 5

Other funds holding VTRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed's VTRS Position: Q1 2021 in Review

OrbiMed sold out of Viatris (VTRS) in Q1 2021, closing a stake of 535,149 shares — an estimated $10M sold.

OrbiMed first reported a position in VTRS in Q2 2013 and held it in 19 quarters. The position peaked at $204M in Q2 2014. 1,115 funds tracked by Wall St. Rank hold VTRS as of Q1 2021.

  • OrbiMed reported no remaining Viatris position as of Q1 2021 after selling out during the quarter.
  • OrbiMed sold 535,149 Viatris shares in Q1 2021, an estimated $10M.
  • OrbiMed first reported a position in Viatris in Q2 2013 and held it in 19 quarters.
  • OrbiMed's Viatris position peaked at $204M in Q2 2014.
  • 1,115 funds tracked by Wall St. Rank held Viatris as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.